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Electronic monitoring to diagnose and
treat drug nonadherence
Arnaud Chioleroa,b and Vale´rie Santschic,d
H
amdidouche et al. [1] elegantly summarized recent
findings about drug adherence in hypertension,
with the goal of helping clinicians and researchers
to address the problem more efficiently. The authors listed
strengths and limitations of ‘indirect’ methods to measure
drug adherence, including clinical estimation and patient
questionnaires, pill counting, prescription refill, and
electronic monitoring. The later method uses an electronic
pillbox that records each time the cap is opened. The
authors argue that such monitoring can provide a timing
of drug intake but that it is unable to certify the ingestion
of correct dose, as opening the box does not mean that
the pill was ingested [1]. Although this limitation is well
known, several advantages and new technological devel-
opments of electronic monitoring have been however
overlooked.
Electronic monitoring has been advocated as early as
1989 by Cramer et al. [2] to quantify reliably ambulatory
patient’s drug adherence. Initially, this tool consisted of a
pill bottle with a microprocessor in the cap that records
dates and times of each opening, with one opening corre-
sponding to one presumptive dose drug taken. Other
electronic drug reminder devices and web applications
recently developed have largely expanded possibilities of
electronic monitoring of adherence. Compared to other
indirect methods, electronic monitoring provides a
dynamic, and real time – day-to-day – measure of patient’s
drug intake and omissions [2,3]. This is of major importance
because adherence is not a fixed feature of patients but a
dynamic process: the degree of adherence changes accord-
ing to treatment regimen, patients’ perceptions of the dis-
ease and its treatment, or external influences such as
traveling or holidays [3].
The key role is that electronic monitoring is unique to
take rational treatment decisions [4]. Indeed, if a patient
treated for a condition such as hypertension is not con-
trolled, the physician assumes, most often, the inefficiency
of the treatment and changes it. If adherence is not optimal,
changing medications will not improve blood pressure
control. Unless the patient recognizes being not adherent,
physicians cannot differentiate treatment failure because of
inadequate treatment or nonadherence. Further, electronic
monitoring makes it possible not only to diagnose poor
adherence but also to treat it. Several studies suggest,
indeed, that it helps control chronic conditions such as
hypertension [1,4]. For instance, in a pragmatic randomized
controlled study conducted in a community of pharmacist
and physicians’ networks, hypertensive patients allocated
to electronic monitoring achieved a better blood pressure
control [4].
Nevertheless, we agree that electronic monitoring, using
pillboxes or other tools allowing real-time adherence, is not
sufficient per se to treat nonadherence in patients with
chronic conditions. A comprehensive and personalized
approach, involving several strategies, is critical to improve
drug adherence [1,5]. In our opinion, adherence should be
addressed within novel approaches of care of chronic
conditions [6]. With the development of collaborative care
model including different healthcare professionals (phys-
icians, nurses, pharmacists) [7], the increasing implication of
the patient, and the development of ehealth technologies,
intervening to diagnose and treat poor adherence is
becoming truly possible.
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Who is an expert?
Eoin O’Brien
I
would like to question the critical comments by
Messerli et al. [1] entitled ‘Expertise: no longer a sine
qua non for guideline authors?’, in which they question
the credibility of the authors of the recently published
‘Clinical Practice Guideline from the American College of
Physicians and the American Academy of Family Phys-
icians’ pertaining to ‘Pharmacologic Treatment of Hyper-
tension in Adults Aged 60 Years or Older’ (ACP/AAFP) [2].
The issue raised is simply this: Do the authors qualify as
experts? To demonstrate that they did not fulfill the com-
monly held criteria by which experts may be defined,
Messerli et al. selected as their gold standard the experts
who authored the ‘Evidence-based guideline for the man-
agement of high blood pressure in adults: report from the
panel members appointed to the Eighth Joint National
Committee (JNC 8)’ [3].
On the face of it, the data presented in the table make a
damning case against the authors of the ACP/AAFP guide-
line (Table 1). Indeed, the authors extol the virtues of the
JNC 8 experts in glowing terms: ‘When one scrutinizes the
authors of what is called the Joint National Committee (JNC)
8 [3], there is little doubt that most of them were indeed true
experts, displaying skills or knowledge acquired through
education, training, or experience to guide other physicians
in detection, evaluation, and treatment of patients with
hypertension. Many of these authors have extensively
published on hypertensive cardiovascular disease, are
members of professional societies and editorial boards of
peer reviewed journals on hypertension’ [1]. Whew, all but
the most skeptical would be swept away by the gale of this
rhetoric! However, what Messerli et al. failed to acknow-
ledge was the sheer inability of the JNC 8 ‘experts’ to
produce a credible guideline as I have outlined in detail
previously [4]. Indeed, this failure to see the elephant in the
room is baffling in view of the fact that in withdrawing from
authorship of the editorial, I warned against using the JNC 8
guideline as the comparator: ‘I think it best if you remove
my name, simply because, I have written a critical essay on
JNC 8 showing that even if you have a panel of so-called
‘experts’, they can make just as much a mess of things as
‘nonexperts’. In fact, I have questioned the credibility of the
JNC 8 Committee of experts, which will be picked up by
someone if I am a listed author, and a counter attack would
weaken your justifiable case. Had you selected any other
guideline for comparison I would have been glad to join
your protest’ [Personal communication from E. O’Brien
(present author) to Messerli et al., 10 February 2017].
Just by way of reminding ourselves of the incompetence
of the JNC 8 ‘experts’, who oversaw what I have called the
JNC 8 debacle, I will list the salient ones: First, a disclaimer
at the end of the JNC 8 report, points out that although
the National Heart, Lung, and Blood Institute (NHLBI)
appointed a panel in 2008 to write JNC 8, it informed the
panel in 2013 that it would partner in the future with other
organizations to develop hypertension guidelines, effec-
tively dismissing them as experts; second, the guideline did
not complete the process laid down by the NHLBI and it
was disingenuous of the authors of the report (and indeed
of JAMA) to permit the inclusion of the term JNC 8 in the title
to the report, thereby implying that it was the long-awaited
successor to JNC 7; finally, and most damningly, five of
the 17 authors of the JNC 8 article published a disclaimer to
one of the recommendations in the report, namely, their
disagreement with the all-important stipulation to raise the
target SBP from 140 to 150mmHg in persons aged 60 years
TABLE 1. Comparison of publications, Society of Hypertension certification and membership, and editorial board membership (as per 01/
2017)
No. of
publications on
hypertensiona
Society certified
specialistb
Society
membershipc
Editorial board
membershipd
JNC 8 no. of authors¼17 39 (5.5–121) 8 12 17
ACP/AAFP no. of authors¼6 0.5 (0–2.5) 0 0 0
Associated members ACP/AAFP no.¼28 0 (0–0.75) 0 0 0
2013 ESC/ESH no. of authors¼25 98 (40.5–197) 17 18 23
aMedian (interquartile range).
bhttp://www.ash-us.org/Physician-Directory.aspx and http://www.eshonline.org/communities/hypertension-specialist/directory-of-specialists/, respectively.
cAmerican Society of Hypertension (ASH) and European Society of Hypertension (ESH), respectively.
dHypertension, Journal of Hypertension, American Journal of Hypertension, Journal of the American Society of Hypertension, Journal of Human Hypertension, and Journal of Clinical
Hypertension.
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